SynthesisFrontiers in oncology2026
The research landscape and evolutionary trends of platelet-derived extracellular vesicles: a bibliometric and LDA analysis (2015-2026).
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Since the 2013 Nobel Prize in Physiology or Medicine was awarded, extracellular vesicles(EVs) have made the transition from the laboratory to clinical practice. Platelets, as emerging multifunctional immune cells, have garnered significant attention due to the natural biocompatibility and low immunogenicity of platelet-derived extracellular vesicles (pEVs). However, research in this field currently lacks comprehensive review and analysis. Methods: This study utilized the Web of Science database, along with tools such as VOSviewer and CiteSpace, and employed bibliometric analysis and Latent Dirichlet Allocation (LDA) to systematically examine international collaboration, thematic evolution, and research hotspots in this field. In addition, clinical trials related to pEVs were extracted from the PubMed database to assess translational progress. Results: Since 2021, the volume of publications in the field of pEVs has remained stable at a high level. The International Journal of Molecular Sciences was the most productive journal. The United States and China were the leading contributing countries, with the United States occupying a central position in global collaboration networks. Harvard Medical School and Eric Boilard were among the most influential institution and author, respectively. Research hotspots have shifted from basic platelet biology and cardiovascular studies toward regenerative medicine and oncology. Clinical trials remain limited and primarily focus on pathophysiological mechanisms, biomarker applications, and therapeutic exploration. Discussion: This study provides a comprehensive visualization of the global research landscape and developmental trends in pEVs from 2015 to 2026. Although basic research has expanded rapidly, clinical translation remains limited, indicating a clear gap between laboratory findings and clinical application. Emerging trends highlight increasing attention toward regenerative medicine, oncology, and advanced therapeutic strategies, providing directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.